Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Eur J Endocrinol 156(1):65-74 (2007) PMID 17218727
It is believed that the variable effectiveness of somatostatin analogs in post-surgical management of somatotropinomas and non-functioning pituitary adenomas (NFPA) may be due in part to variable expression of somatostatin receptor isoforms (SSTR1-5), within and between pituitary tumor types.
DOI: 10.1530/eje.1.02313
Version: za2963e q8zaa q8zb5 q8zc7 q8zd6 q8ze6 q8zf8 q8zge